Clinical Trials on Carcinosarcome utérin

Total 4291 results

Fondazione Policlinico Universitario Agostino Gemelli...

Completed

Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS) (MITO 26)

Carcinosarcoma, Ovarian | Carcinosarcomas Uterine

Italy
Medical University of Graz

Terminated

Vorinostat (SAHA) in Uterine Sarcoma

Leiomyosarcoma | Endometrial Stromal Tumors | Carcinosarcomas Uterine

Austria
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC

Recruiting

A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma

Uterine Carcinosarcoma | Advanced Uterine Carcinosarcoma

United States
Australia New Zealand Gynaecological Oncology Group
Merck Sharp & Dohme LLC; Eisai Inc.

Recruiting

EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma (EPOCH)

Uterine Carcinosarcoma | Ovarian Carcinosarcoma

Canada, Australia, United Kingdom
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus

Recurrent Uterine Corpus Sarcoma | Uterine Carcinosarcoma

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer

Uterine Carcinosarcoma | Recurrent Uterine Sarcoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer

Recurrent Uterine Corpus Sarcoma | Uterine Carcinosarcoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer

Recurrent Uterine Corpus Sarcoma | Uterine Carcinosarcoma

United States
Sanofi
Gynecologic Oncology Group

Completed

Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma

Uterine Carcinosarcoma

United States
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer

Uterine Carcinosarcoma | Recurrent Uterine Sarcoma | Stage III Uterine Sarcoma | Stage IV Uterine Sarcoma

United States, Canada
National Cancer Institute (NCI)

Terminated

Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus

Uterine Carcinosarcoma | Recurrent Uterine Sarcoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer

Recurrent Uterine Corpus Sarcoma | Uterine Carcinosarcoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer

Sarcoma

United States, Japan
University of Alabama at Birmingham

Withdrawn

Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma

Carcinosarcoma of Ovary | Carcinosarcoma of Uterus | Carcinosarcoma of Vagina

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Endometrial Serous Adenocarcinoma | Uterine Corpus Carcinosarcoma

United States, Puerto Rico
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Uterine Carcinosarcoma | Recurrent Uterine Corpus Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Stage IVA Uterine Corpus Cancer AJCC v7 | Stage IVB Uterine Corpus Cancer AJCC v7 | Uterine Corpus Carcinosarcoma

United States, Canada
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Terminated

Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer

Uterine Carcinosarcoma | Stage IIA Uterine Sarcoma | Stage IIB Uterine Sarcoma | Stage IIIA Uterine Sarcoma | Stage IIIB Uterine Sarcoma | Stage IIIC Uterine Sarcoma | Stage IVA Uterine Sarcoma | Stage IVB Uterine Sarcoma | Stage IA Uterine Sarcoma | Stage IB Uterine Sarcoma | Stage IC Uterine Sarcoma

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Suitability of DCE-MRI for Detection of Vascular Changes After VBT

Carcinoma of the Cervix, Carcinoma or Carcinosarcoma of the Uterus

United States
Ohio State University Comprehensive Cancer Center
ImmunoGen, Inc.; Clovis Oncology, Inc.

Active, not recruiting

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Folate Receptor Alpha Positive | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Recurrent Uterine Serous Carcinoma | Recurrent Uterine Carcinosarcoma | Platinum...

United States
University of Oklahoma
Eli Lilly and Company

Active, not recruiting

Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary

Carcinosarcoma, Ovarian

United States
Medical College of Wisconsin
Genentech, Inc.; Clovis Oncology, Inc.

Completed

The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) (EndoBARR)

Uterine Carcinosarcoma | Endometrial Cancer

United States
Dana-Farber Cancer Institute
AstraZeneca

Active, not recruiting

AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

Uterine Cancer

United States
National Cancer Institute (NCI)

Completed

Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma

Fallopian Tube Cancer | Uterine Carcinosarcoma | Stage IV Ovarian Epithelial Cancer | Ovarian Sarcoma | Recurrent Uterine Sarcoma | Stage III Uterine Sarcoma | Stage IV Uterine Sarcoma | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian Carcinosarcoma | Female Reproductive... and other conditions

United States, Canada
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma

Endometrial Carcinosarcoma

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer

Breast Carcinoma | Endometrial Carcinoma | Prostate Carcinosarcoma

United States
North Eastern German Society of Gynaecological...
Novartis Pharmaceuticals; medac GmbH

Active, not recruiting

Pazopanib vs. Pazopanib Plus Gemcitabine (PazoDoble)

Leiomyosarcoma or Carcinosarcoma

Germany
Assuta Medical Center

Unknown

microRNA Profiles Identification in Adeno Carcinoma Prostate Cancer

Prostate Carcinosarcoma
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb

Active, not recruiting

Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment

Endometrial Adenocarcinoma | Endometrial Carcinosarcoma

United States
Yonsei University

Recruiting

Nivolumab for Recurrent/Metastatic Carcinosarcoma

Recurrent/Metastatic Carcinosarcoma

Korea, Republic of
University of Manchester
Cardiff University; AstraZeneca

Active, not recruiting

Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel? (COPELIA)

Endometrial Neoplasms | Carcinosarcoma

United Kingdom
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

Recurrent Endometrial Adenocarcinoma | Recurrent Endometrial Carcinoma | Recurrent Endometrial Clear Cell Adenocarcinoma | Recurrent Endometrial Endometrioid Adenocarcinoma | Recurrent Endometrial Mixed Cell Adenocarcinoma | Recurrent Endometrial Serous Adenocarcinoma | Recurrent Endometrial Undifferentiated... and other conditions

United States
Floor Backes

Terminated

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

Lynch Syndrome | Recurrent Endometrial Carcinoma | Recurrent Endometrial Clear Cell Adenocarcinoma | Recurrent Endometrial Cancer | Metastatic Endometrial Cancer | Mismatch Repair Deficiency | Recurrent Uterine Corpus Carcinosarcoma

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Active, not recruiting

Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer

Breast Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Uterine Corpus Cancer | Uterine Corpus Carcinosarcoma

United States
University of Utah

Recruiting

Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer (SAVE)

Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Endometrial Clear Cell Adenocarcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Serous Adenocarcinoma | Uterine Corpus Sarcoma | Uterine Corpus Carcinosarcoma | Stage IA Uterine Corpus Cancer | Stage IB Uterine Corpus Cancer

United States
M.D. Anderson Cancer Center

Recruiting

Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in High-Risk Endometrial Cancers

Endometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Serous Adenocarcinoma | Malignant Uterine Neoplasm | Endometrial Mucinous Adenocarcinoma | Uterine Corpus Carcinosarcoma

United States
Memorial Sloan Kettering Cancer Center

Completed

A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer

Endometrial Cancer | Endometrial Carcinoma | Endometrial Carcinosarcoma | Endometrial Cancer Recurrent | Endometrial Carcinoma, Recurrent

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Sanofi; Brigham and Women's Hospital

Completed

Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus

Mixed Mullerian Tumors of the Uterus

United States
HiFiBiO Therapeutics

Active, not recruiting

A Study of HFB301001 in Adult Patients With Advanced Solid Tumors

Melanoma | Soft Tissue Sarcoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Uterine Carcinosarcoma | Head and Neck Squamous Cell Carcinoma

United States, Spain
National Cancer Institute (NCI)

Completed

AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma

Uterine Carcinosarcoma | Endometrial Stromal Sarcoma | Recurrent Adult Soft Tissue Sarcoma | Recurrent Uterine Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage III Uterine Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage IV Uterine Sarcoma | Dermatofibrosarcoma Protuberans | Adult Rhabdomyosarcoma and other conditions

Canada, United States
University of Alabama at Birmingham

Recruiting

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

Carcinoma | Gynecologic Cancer | Endometrial Cancer | Uterine Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Recurrent Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer AJCC v7 | Stage IVA Uterine Corpus Cancer AJCC v7 | Stage IVB Uterine Corpus Cancer AJCC v7 | Endometrial Adenosquamous... and other conditions

United States, Canada
Memorial Sloan Kettering Cancer Center
Zymeworks BC Inc.

Completed

ZW25 in Women With Endometrial Cancers

Carcinosarcoma | Endometrial Cancer

United States
Tanta University

Completed

Abdominal Versus Vaginal Bisection in Laparoscopic Hysterectomy (TLH-Bisection)

Hysterectomy | Laparoscopy | Uterine Bisection | Large Uteri

Egypt
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma

Uterine Carcinosarcoma | Ovarian Sarcoma | Recurrent Adult Soft Tissue Sarcoma | Recurrent Uterine Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage III Uterine Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage IV Uterine Sarcoma | Adult Angiosarcoma | Adult Epithelioid Sarcoma | Adult Leiomyosarcoma | Adult Synovial Sarcoma and other conditions

United States
ARCAGY/ GINECO GROUP
Tesaro, Inc.

Active, not recruiting

Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib (ROCSAN)

Ovarian Carcinosarcoma | Endometrial Carcinosarcoma

France
Mayo Clinic

Recruiting

A Study of FRaDCs for Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Fallopian Tube Carcinosarcoma | Primary Peritoneal Carcinosarcoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian... and other conditions

United States
Hung-Hsueh Chou
Bristol-Myers Squibb; GlaxoSmithKline

Unknown

A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma

Recurrent Endometrial Cancer
Rambam Health Care Campus

Terminated

Cervical Cerclage Position Throughout the Pregnancy.

Cervix Uteri-Diseases

Israel
Vanderbilt-Ingram Cancer Center
AstraZeneca; Syndax Pharmaceuticals

Terminated

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Fallopian Tube Cancer | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Recurrent Endometrial Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Primary Peritoneal... and other conditions

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Recruiting

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma and other conditions

United States

Clinical Trials on Carcinosarcome utérin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations